Top Markets
Coin of the day
Egetis Therapeutics AB (publ) Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

EGTX
Rank in Stocks #14551
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to... Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
Share Price
$0.87679425
Last synced: 2026-08-31
Market Cap
$407.66M
Change (1 day)
-1.88%
Change (1 year)
58.03%
Country
SE
Trade Egetis Therapeutics AB (publ) (EGTX)

Category

P/S ratio for Egetis Therapeutics AB (publ) (EGTX)
P/S ratio as of 2026 TTM: 0
According to Egetis Therapeutics AB (publ) latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Egetis Therapeutics AB (publ) from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.95 -
US
12.19 -
NL
3.75 -
AU
24.99 -
US
- -
CH